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CHAPTER I
INTRODUCTION
The work in this dissertation is about modeling the spread of an infectious disease
in a closed community with two basic public health interventions: (i) identifying and
isolating symptomatic cases, and (ii) tracing and quarantine of the contacts of identified
infectives. Our aim is to evaluate the efficacy of tracing and quarantine strategies which
are believed to be an important aspect of controlling an outbreak of emerging or re-
emerging infectious diseases. The model is applicable in both emerging epidemics that
require isolation, tracing, and quarantine, such as H1N1, SARS (severe acute respiratory
syndrome), and influenzas, and re-emerging epidemics that requires isolation and certain
vaccination strategies, such as a smallpox bioterrorist attack. Moreover, our model can
be applied as a rational basis for decision makers to guide interventions and deploy public
health resources in future epidemics.
I.1 Terminologies
There are two alternatives for epidemic controls, namely targeted control and mass con-
trol. Isolation of symptomatic cases is important in controlling infectious diseases, but
also important is the vaccination and quarantine of traced contacts of known infectives.
Contact tracing is especially important when there is a lack of rapid diagnostic methods,
as was in the case of SARS Glasser et al (2011).
We next clarify the definitions of the three intervention strategies considered in the
1
model1:
1. Isolation is the process by which infected people (all of whom are symptomatic) are
prevented from infecting susceptible ones.
2. Contact tracing is the process of identifying people who may have been infected by
exposure to (or contact with) an infectious person.
3. Quarantine is the process of isolating these people, called contacts (none of whom
is yet symptomatic, and many not even be infected).
Quarantine can be divided into two types: (i) quarantine of close contacts of identified
cases, and (ii) quarantine of large groups of people (such as residents in residential com-
plexes, workers in a workplace, students in schools, etc). Our model focuses on the (i)
type quarantine, which is conducted as a consequence of tracing close contacts of infected
individuals.
I.2 Background
There are two practical applications of our model being presented in this dissertation:
(1) we assess public health guidelines about emergency preparedness and response in the
event of a smallpox bioterrorist attack; (2) we simulate the 2003 SARS outbreak in Taiwan
and estimate the number of cases avoided by contact tracing.
I.2.1 Smallpox
Smallpox was eradicated in 1979, but fears of bioterrorist attacks by deliberately releasing
the variola virus have been taken into consideration according to federal and academic
1Definitions are provided by J. Glasser at Centers for Disease Control and Prevention.
2
observations ever since the terrorist attacks of September 11, 2001. Although the two gov-
ernment laboratories in the United States and Russia are the only known places that keep
the viral samples, the possibility of other sources cannot be ruled out CIDRAP (2002).
Public health authorities have detailed plans for emergency preparedness and response to
a smallpox outbreak CDC (2003); on the other hand, the proper amount of vaccine and
treatment medicine that should be stockpiled is still controversial NewYorkTimes (2013).
Due to the undesirable side-effects of the vaccine, the routine vaccination for the vari-
ola virus has been discontinued ever since 1972, and currently the vaccination is only given
to selected military personnel and laboratory workers who handle the virus. Moreover,
because of the waning immunity of the vaccine, the proportion of Americans who are both
over age 40 and still immune to smallpox might be too small to achieve herd immunity.
As a result, based on these concerns, public health authorities, such as Centers for Dis-
ease Control and Prevention (CDC), suggest intensive surveillance and identification of
infected cases, isolation of smallpox patients, and vaccination of close contacts of infected
individuals.
I.2.2 SARS
Distinct from smallpox, the conduct of surveillance and control strategies of modern
influenzas (such as H1N1 and SARS) is less efficient due to the lack of timely vaccines, non-
compliance of the public with quarantine, and the period of asymptomatic infectiousness.
It is widely believed that SARS was eradicated because of limited transmission occurring
before symptom onset, but the effectiveness of contact tracing is still controversial even
in the regions where high levels of contact tracing were conducted, such as Taiwan and
mainland China. So we apply our model to simulate the SARS outbreak in Taiwan with
real data to assess the contact tracing and quarantine efficacy in avoiding infections.
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I.3 Related Studies
We apply our model to assess the ring vaccination strategy in the control of smallpox,
and compare the effectiveness between ring vaccination strategy and mass vaccination
strategy. Various methods have been developed to evaluate public health control strategies
for smallpox. Mu¨ller et al. investigate contact tracing by an individual based stochastic
model Mu¨ller et al (2000). Meltzer et al. develop a Markov chain model to estimate
in what levels that a combined vaccination and quarantine campaign should be taken
to reduce smallpox transmission, and suggest a number of adequate vaccine doses for
stockpiling Meltzer et al (2001). Halloran et al. construct a stochastic model to compare
the effectiveness of mass vaccination versus targeted vaccination in a population of 2,000,
and they conclude that targeted vaccination can prevent more cases per dose Halloran
et al (2002). Eichner performs stochastic computer simulations to examine how case
isolation and contact tracing prevent the spread of smallpox Eichner (2003). Kretzschmar
et al. present a branching process stochastic model to estimate the size and duration
of outbreaks contained by ring vaccination Kretzschmar et al (2004). Vidondo et al.
approach a novel containment strategy which vaccinates “super contacts”by an individual-
network based simulation Vidondo et al (2012).
There are also several ordinary differential equation (ODE) models which focus on
different aspects of controlling a smallpox outbreak. Kaplan et al. assume a high infectivity
in the prodromal period in their model with a focus on public health logistical constraints.
They conclude that mass vaccination is more efficient than ring vaccination, when a
congestion in the vaccination queue occurs Kaplan et al (2003), Kaplan et al (2002).
Castillo-Chavez et al. take the behavioral changes of the community into consideration,
and demonstrate that even gradual and mild changes of people’s daily contact activity
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can slow an epidemic Valle et al (2005). Hsieh et al. propose a differential equation model
that includes intervention measures implemented in the control of 2003 SARS, and analyze
how quarantine measures change the basic dynamics of the model Hsu and Hsieh (2006).
ODE models were used in modeling SARS as well, and in particular to investigate
the impact of quarantining asymptomatic infectives Hethcote et al (2002), Wang and
Ruan (2003), Hsieh et al (2004), Gumel et al (2004), Nishiura et al (2004), Fraser et al
(2004), Day et al (2006), Hsu and Hsieh (2006), Arino et al (2006), Feng et al (2007),
Feng et al (2009), Feng et al (2011). A thorough review of many of these works has been
provided in Bauch et al (2005). The article points out that the nonlinearity of the rate of
quarantining undiagnosed cases is required to be taken into account. In our work, we use
a partial differential equation (PDE) model with a variable of disease age (or age since
infection), with nonlinear rates of contact tracing infectives and quarantining susceptibles
dependent on the rate of identifying symptomatic cases.
Although some of the previous work includes the varying levels of transmission ability
and symptom scores in different disease stages, there is less work about smallpox control
that takes continuous disease age into consideration. Webb et al. apply age structured
epidemic models to investigate isolation strategy and school closings in the spread of
H1N1 Webb et al (2010). Inaba et al. develop a series of multistate class age structured
epidemic systems with isolation rate as the only intervention Inaba and Nishiura (2008).
Fraser et al. establish an infection age-structured model that estimates the effectiveness
of isolation and contact tracing in the control of epidemic diseases with a formulation
different from ours Fraser et al (2004). Our model is aimed to take into consideration
several key features about disease transmission and public health interventions at the
same time:
(i) Continuous infection age.
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(ii) Infection-age-dependent case isolation rate.
(iii) Contact tracing/quarantine/vaccination rates that depend on diagnosis rate of symp-
tomatic cases.
(iv) Variation of susceptible population due to infection and contact tracing, quarantine,
or vaccination.
6
CHAPTER II
PRELIMINARY: THE ODE MODEL
Before we introduce our age-structured partial differential equations model, in this
chapter, we review the fundamental theory of modeling epidemic infectious disease with
ordinary differential equations models. This review aims to interpret important parame-
ters of the ODE model, as well as provide accurate understanding of the parameters in
the main PDE model.
Epidemic models with ODE form a typical category of compartmental models, which
divide the population into disjoint groups (compartments) based on disease status, age,
or other factors. The so-called SIR model labels three compartments: S stands for the
susceptible population, I is for the infected population, and R represents the recovered
population. In the ODE model, the compartments are single-variable functions with
respect to time. ODE and PDE models are deterministic models, in which the future
states are determined by the knowledge of the present state of the system Bauch et al
(2005). ? gives a time line for the development of deterministic modeling in epidemic
diseases ever since the beginning of the 20th century: Hamer (1906) formulated a discrete
time model to understand the recurrence of measles epidemics, which is also the first model
with the infection rate proportional to the product of the susceptible population and the
infected population. Later Ross, Hudson, Martini, and Lotka developed other models to
study diseases such as malaria. In 1911, Kermack and McKendrick published papers of
theoretical results and formulations in epidemic models, and their models incorporated
the important feature of disease age related transmission and removal rates.
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II.1 Basic SIR Compartmental Model
As mentioned before, we denote S(t) as the population of people who are not infected
and are susceptible to the disease at time t, I(t) as the population of people who are
infected and infectious at time t, and R(t) as the population of recovered people, who will
neither infect others nor be reinfected at time t. We ignore the natural birth and death
rates because the outbreak of an epidemic moves faster than the demographic rates in the
population. So we have the following dynamics:
dS
dt
= −λIS, S (0) = S0 ≥ 0
dI
dt
= λIS − rI, I (0) = I0 ≥ 0
dR
dt
= rI, R (0) = R0 ≥ 0
(II.1)
where r is the recover rate if there is no control, and if there is a control of isolating
symptomatic individuals, r can be regarded as the combination of two rates: the rate of
naturally recovery without showing symptoms or being isolated, and the rate of being
isolated due to showing symptoms.
In (II.1), λI is the rate of new infections (the force of infection). We denote N as
the total number of people in the community, which is a constant, α as the average
number of contacts one might have per unit time (per day), and β as the probability
of an infected individual to transmit the disease to a susceptible person when they have
contacts. For each infected individual at time t, there is a probability S (t)/N to meet
a susceptible person, amd there is a probability β for an infection to happen during this
contact. Then each infected individual will infect β · S (t)/N susceptibles per contact,
and infect α · β · S (t)/N susceptibles per unit time. So there will be α · β · S (t) · I (t)/N
susceptibles infected per unit time, which gives the disease infection rate.
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According to the calculation above, the parameter λ in (II.1) cannot be simply under-
stood as the disease transmission rate, it is actually a product of parameters with practical
meanings: λ = α · β/N . Although a single character β has often been used to represent
the infection transmission coefficient, correct understanding of the incidence rate is very
important in the application.
II.2 SIR Model with Mass Control
Mass control strategies, for which a good example is the mass vaccination strategy in
controlling smallpox, is a process that prevents people (both susceptible and infected)
from random disease transmission, by interventions such as quarantine and vaccination.
We provide the ODE model for mass control as follows (the age-structured model and
background discussions are elaborated in V.2.1):
dS
dt
= −λIS −mS, S (0) = S0 ≥ 0
dI
dt
= λIS − rI −mI, I (0) = I0 ≥ 0
dR
dt
= rI, R (0) = R0 ≥ 0
(II.2)
where the interpretations of λ and r are the same with those in (II.1), and m = M/N ,
where M is the number of people removed due to mass control per unit time and N is
the total population number. So the removal rate of susceptible population due to mass
control m is interpreted as the total number of people removed by mass control per unit
time, times the probability for one person being susceptible (S (t)/N).
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II.3 SIR Model with Targeted Contact Tracing
According to targeted tracing strategies, such as contact tracing in SARS and ring vacci-
nation in smallpox, it is reasonable to assume that the targeted tracing rate is related to
the isolation rate of symptomatic individuals. In the practical control of an epidemic dis-
ease, an identified symptomatic individual will be asked to provide a list of close contacts
to be traced as soon as possible. If we ignore the delay of the tracing process, then the
number of people removed due to tracing will be proportionate to the number of identified
cases. With this idea in mind, we have the corresponding ODE model:
dS
dt
= −λIS − κsSI, S (0) = S0 ≥ 0
dI
dt
= λIS − rI − µI − κiI2, I (0) = I0 ≥ 0
dR
dt
= rI, R (0) = R0 ≥ 0
(II.3)
where in this case, λ and N are as in (II.1), r is the natural recover rate, and µ is the
isolation rate of symptomatic individuals. We now interpret: κs = ηs · µ · C/N , where ηs
is the probability for a contact, provided by a symptomatic infective, to be susceptible,
which depends on the contact tracing efficiency. C is the average number of contacts that
can be effectively provided and traced per identified infective. The probability for each
susceptible individual to be a contact of an identified infective is µ · I (t)/N . Hence the
probability to be named as a traced contact is ηs · C. So we have the contact tracing rates
for all susceptibles as κsI in (II.3). Similar interpretation applies for the contact tracing
rate of infected individuals.
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CHAPTER III
MAIN MODEL: AGE-STRUCTURED PDE MODEL
III.1 Notations
Before introducing the main model, we introduce the notations as follows:
(N.1) For 0 < M 6 ∞, let L1 := L1 ([0,M] ;R), L1+ := L1 ([0,M] ;R+) which is the
positive cone in L1. M denotes the maximum disease age in the model.
(N.2) For 0 < T 6 ∞, denote CT := C ([0, T ] ;L1) with the supremum norm: ‖l‖CT :=
sup
06t6T
‖l (t)‖L1 , for l ∈ CT . Let CT,+ := C
(
[0, T ] ;L1+
)
which is the positive cone in
CT .
The basic assumptions are as follows:
(A.1) Let T ∈ (L1)∗ with norm ‖T ‖∞, and we assume T
(
L1+
) ⊆ R+.
(A.2) B,Q : L1 → R be globally Lipschitz continuous functions with Lipschitz constants
|B| and |Q|. Moreover, we assume B (L1+) ⊆ R+ and Q (L1+) ⊆ R+.
(A.3) B (0) = 0, Q (0) = 0.
III.2 Model
For t > 0, a ∈ [0,M], the formal model is:
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∂∂t
i (a, t) +
∂
∂a
i (a, t) = −µ (a) i (a, t)︸ ︷︷ ︸
isolation of symptomatic
individuals with infection
age a
−T (i (·, t)) i (a, t)︸ ︷︷ ︸
tracing of contacts
with infection age a
d
dt
S (t) = −B (i (·, t))S (t)︸ ︷︷ ︸
infection of susceptibles
−Q (i (·, t))S (t)︸ ︷︷ ︸
quarantine of contacts
that are susceptible
i (0, t)︸ ︷︷ ︸
infectives with
infection age 0
= B (i (·, t))S (t)︸ ︷︷ ︸
rate of new infections
i(a, 0) = i0(a) ∈ L1 [0,M]
S(0) = S0 ∈ R+
(III.1)
where i(a, t) is the infected population density at infection age a at time t, and S(t) is the
susceptible population at time t, µ(a) is the rate of isolating symptomatic cases those are at
disease age a. If we denote i (·, t) as the infected population density function at time t, then
B (i (·, t)) represents the infection transmission rate, T (i (·, t)) represents the isolation
rate of infected individuals due to contact tracing at time t, and Q (i (·, t)) represents the
quarantine rate of susceptible contacts as the consequence of contact tracing.
III.3 Problem Formulation
Solving for S (t) from the second equation in (III.1), we can simplify the problem into an
age-dependent population dynamics model for i (a, t):
∂
∂t
i (a, t) +
∂
∂a
i (a, t) = −µ (a) i (a, t)− T (i (·, t)) i (a, t)
i (0, t) = S0B (i (·, t)) e−
∫ t
0 B(i(·,s))+Q(i(·,s))ds
i(a, 0) = i0(a)
(III.2)
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In the following context, we denote i (t)(a) := i (a, t); then i ∈ CT means i(t) ∈ L1, for
t ∈ [0, T ]. We also refer the solutions of the age-dependent problem as l (t)(a) := i (a, t),
where l ∈ CT . Next we will generalize the problem to a formulation of age-dependent
population dynamics. We introduce the aging and birth functions:
(1) Let G : L1 → L1 be the aging function.
(2) For 0 < T 6∞, let F : CT = C ([0, T ] ;L1)→ C ([0, T ] ;R) be the birth function.
Let 0 < T 6 ∞, let t ∈ [0, T ] and l ∈ CT , the general age-dependent problem is as
follows:
∂
∂t
l (t)(a) +
∂
∂a
l (t)(a) = G(l (t))(a) , a.e. a ∈ [0,M]
l (t)(0) = (F (l))(t)
l (0)(a) = φ (a) , a.e. a ∈ [0,M]
(III.3)
However, the equation system in (III.3) is not well defined for solutions that are not
continuously differentiable with respect to both variables. We are thus led to the following
formulation of age-dependent population dynamics as in Webb (1985): let 0 < T 6 ∞,
and let l ∈ CT satisfy:
lim
h→0+
∫ M
0
∣∣h−1 [l (t+ h)(a+ h)− l (t)(a)]−G(l (t))(a)∣∣ da = 0
lim
h→0+
∫ h
0
|l (t+ h)(a)− (F (l))(t)| da = 0
l (0)(a) = φ (a) , a.e. a ∈ [0,M]
(III.4)
where we let l (t+ h)(a+ h) = 0 if a+ h > M.
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III.4 Preliminary Results
In this section, we will present results about local existence and uniqueness of the solutions
to the age-dependent problem (III.4) with the following assumptions on the aging and
birth functions:
(H.1) G : L1 → L1, there is an increasing function c1 : [0,∞) → [0,∞) such that
‖G (φ1)−G (φ2)‖L1 ≤ c1 (r) ‖φ1 − φ2‖L1 for all φ1, φ2 ∈ L1 such that ‖φ1‖L1 , ‖φ2‖L1 ≤
r.
(H.2) There is a function c2 : [0,∞)× [0,∞)→ [0,∞), which is increasing and continuous
w.r.t. both variables. Then for all T > 0, F : CT → C ([0, T ] ;R), for any 0 ≤ t ≤ T
and r > 0, we have
|(F (φ1))(t)− (F (φ2))(t)| 6 c2 (r, t) sup
06s6t
‖φ1 (s)− φ2 (s)‖L1
for all φ1, φ2 ∈ CT such that ‖φ1‖CT , ‖φ2‖CT ≤ r.
We state theorems about local existence and uniqueness of the solutions below. The proofs
(they can be found in the Appendix) are different from those in Webb (1985), since our
assumption of the birth function F is different.
III.4.1 Theorem III.4.1
Theorem III.4.1. Let (H.1) and (H.2) hold and let φ ∈ L1. There exists T > 0 and
l ∈ CT such that l is a solution of (III.4) on [0, T ]. Furthermore, there is a unique solution
of (III.4) on [0, T ].
We introduce the definition of maximal interval of existence as in Webb (1985):
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III.4.2 Definition III.4.2
Definition III.4.2. Let φ ∈ L1. Denote [0, Tφ) as the maximal interval of existence of
the solution of (III.4), is the maximal interval with the property that if 0 < T < Tφ, there
exist l ∈ CT such that l is a solution of (III.4) on [0, T ].
With additional assumptions as stated below, we will prove the positivity of the solu-
tions.
(H.3) F (CT,+) ⊆ C ([0, T ] ;R+)
(H.4) There is an increasing function c3 : [0,∞)→ [0,∞) such that if r > 0 and φ ∈ L1+
with ‖φ‖L1 ≤ r, then G (φ) + c3 (r)φ ∈ L1+.
III.4.3 Theorem III.4.3
Theorem III.4.3. Let (H.1)-(H.4) hold and let φ ∈ L1+. The solution l of (III.4) on
[0, Tφ), has the property that l (t) ∈ L1+ for 0 6 t < Tφ.
Furthermore, with one more restriction on the aging and birth functions, the positive
solution exists globally.
III.4.4 Theorem III.4.4
Theorem III.4.4. Let (H.1)-(H.4) hold and let φ ∈ L1+, let l be the solution of (III.4) on
[0, Tφ), and let there exist ω ∈ R such that for 0 ≤ t < Tφ, F and G satisfy the following
inequality:
(F (l))(t) +
∫ M
0
G (l (t))(a) da 6 ω
∫ M
0
l (t)(a) da (H.5)
Then Tφ =∞ and ‖l (t)‖L1 ≤ eωt‖φ‖L1.
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CHAPTER IV
BASIC THEORY OF THE EPIDEMIC MODEL
We will continue investigating the solutions of the specific age-dependent problem
(III.2) in the sense of (III.4). First, specify the birth and aging functions:
(P.1) The aging function G : L1 → L1 is, for φ ∈ L1,
G (φ)(a) = −µ (a)φ (a)− T (φ)φ (a).
(P.2) The birth function F : CT → C ([0,∞] ;R) is, for l ∈ CT ,
(F (l))(t) := S0B (l (t)) e−
∫ t
0 B(l(s))+Q(l(s))ds.
where µ and S0 are as in (III.1), T , B, and Q are as in (A.1)-(A.3).
IV.1 Theorem IV.1.1
Theorem IV.1.1. Let (A.1), (A.2) and (A.3) hold, let µ ∈ L∞+ [0,M], S0 > 0, and
φ ∈ L1+ [0,M]. There is a function l ∈ C
(
[0,∞) ;L1+
)
such that l is the unique global
solution of (III.4) with the aging function G and birth function F in (P.1) and (P.2).
For computational convenience and the proof of the asymptotic behavior, we introduce
a solution formula in the following two theorems.
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IV.2 Proposition IV.2.1
Proposition IV.2.1. Let (A.1), (A.2) and (A.3) hold, let µ ∈ L∞+ [0,M], S0 > 0, and
φ ∈ L1+. There exists u ∈ C
(
[0,∞] ;L1+
)
such that u satisfies:
u(t)(a) =
(H (u))(t− a) e
− ∫ a0 µ(b)db, a < t
φ (a− t) e−
∫ a
a−t µ(b)db, a ≥ t
(IV.1)
where
(H (u))(t) =S0B
(
u (t)
1 +
∫ t
0
T (u (s)) ds
)
×
(
1 +
∫ t
0
T (u (s)) ds
)
×
e
− ∫ t0 B( u(s)1+∫ s0 T (u(τ))dτ
)
+Q
(
u(s)
1+
∫ s
0 T (u(τ))dτ
)
ds
Moreover, u is a solution of (III.4) with birth function H and aging function P : L1 → L1,
where P (l)(a) = −µ (a) l (a) for l ∈ L1.
IV.3 Theorem IV.3.1
Theorem IV.3.1. Let (A.1), (A.2), and (A.3) hold, let µ ∈ L∞+ [0,M], S0 > 0, and
φ ∈ L1+. Let u ∈ C
(
[0,∞) ;L1+
)
be the solution to the integral equation (IV.1). Then
l (t)(a) =
u (t)(a)
1 +
t∫
0
T (u(τ))dτ
(IV.2)
gives the unique global solution l ∈ C ([0,∞) ;L1+)to problem (III.2).
By formula (IV.2), we will be able to investigate the asymptotic behaviour of the
solution to (III.2) as in the next theorem. Furthermore, (IV.2) also provides a starting
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point for our simulations.
IV.4 Theorem IV.4.1
Theorem IV.4.1. Let (A.1), (A.2) and (A.3) hold, let µ ∈ L∞+ [0,M], S0 > 0, and
φ ∈ L1+. Assume that there is an a0 ∈ [0,M) such that µ (a) > µ0 > 0 for all a ∈ [a0,M].
Then, for the unique solution of (III.1) in the sense of (III.4), lim
t→∞
S (t) = S∞ > 0,
lim
t→∞
I (t) = lim
t→∞
∫M
0
i (a, t) da = 0.
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CHAPTER V
APPLICATIONS
V.1 Parameter Interpretations
In this section, we take the ring vaccination strategy of smallpox as an example to interpret
the important parameters in our model. Also known as surveillance and containment,
ring vaccination consists of rapid identification, isolation, vaccination of close contacts of
infected persons (primary contacts), and vaccination of contacts of the primary contact
(secondary contacts). We assume that each identified individual will be asked to provide
a list of contacts of an average number (denoted by CT as in the following text). Contacts
that are successfully traced will be vaccinated and put under surveillance for a certain
quarantine period. That is, vaccination and surveillance are follow-up procedures of
tracing, and are applied to both susceptible contacts (who are in the quarantine class)
and infected contacts (who are in the contact tracing class). We divide the population at
time t into seven classes as shown in a flow diagram in Fig. V.1.
In the following context, we denote Ti as the length of the pre infectious period
(infectiousness threshold), Ts as the length of the pre-symptomatic period (symptoms
threshold), and Fi as the length of the infectious period. Hence Ti + Fi represents the
maximum disease age. We consider problem (III.1) with the same notations. Notice that
the dynamics of 4 compartments illustrated in Fig. V.1 depend on S(t) and i (a, t), since
19
S(t)
susceptible
E(t)
exposed
I(t)
infectious
RI(t)
isolated due
to symptoms
R(t)
recovered
TS(t)
traced, vaccinated and
under surveillance
TV (t)
traced, vaccinated and
under surveillance
Figure V.1: Susceptible individuals may become infected, immediately enter the exposed class,
E(t), in which they are not yet infectious, and then enter the infectious class, I(t). Symptomatic
infectives in I(t) may exit to the isolated class, RI(t), and they will recover, enter R(t), and
do not return to S(t) because of immunity. Susceptible people may be traced, vaccinated,
put under surveillance, and they do not return to S(t) because of vaccination. Exposed and
infected individuals may be traced, vaccinated, put under surveillance, and then isolated when
they become symptomatic. There is a possibility for infectious individuals who are neither
identified due to symptoms or isolated by contact tracing, to enter class R(t) when they reach
the maximum disease age.
E (t) =
∫ Ti
0
i (a, t) da, I (t) =
∫ Ti+Fi
Ti
i (a, t) da. Moreover, we have
dR(t)
dt
+
dRI(t)
dt
+
dTS(t)
dt
+
dTV (t)
dt
= i (Ti + Fi, t)︸ ︷︷ ︸
recovery rate of
unidentified infectives
+
∫ Ti+Fi
Ts
µ (a)i (a, t)da︸ ︷︷ ︸
isolation rate of
symptomatic cases
+ T (i (·, t))(E(t)+I(t))︸ ︷︷ ︸
tracing and surveillance
rate of infectives
+ Q(i (·, t))S(t)︸ ︷︷ ︸
tracing and vaccination
rate of susceptibles
Since tracing is a consequence of identifying symptomatic cases, the number of contacts
traced should be related to the number of infectious cases identified. Then we assume,
for simplicity, that the tracing (hence vaccinating and surveilling) rate is proportional to
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the isolation (identifying new cases) rate. That is, in model (III.1), we set
T (i (·, t)) = ηI · CT
S0
∫ Ti+Fi
Ts
µ (a) i (a, t) da
Q(i (·, t)) = ηS · CT
S0
∫ Ti+Fi
Ts
µ (a) i (a, t) da
B(i (·, t)) =
∫ Ti+Fi
Ti
β (a) i (a, t) da
(V.1)
where µ(a) is the isolation removal rate for symptomatic infectives at disease age a as
in (III.1), β(a) is the disease transmission rate of an infectious individual at disease age
a, CT is the average number of contacts provided by each identified infective, S0 is the
initial susceptible population as in (III.1), and ηI and ηS are proportionality constants
for tracing the infected class and the susceptible class, respectively. Discussions about
meanings and estimations of the parameters ηI and ηS are in the following context.
Contacts provided by an identified infective may come from any of the seven classes
in Fig. V.1, but only those who are in the classes S(t), E(t), and I(t) may be successfully
traced, vaccinated, and put under surveillance. We assume that the probability for a
contact being infected (or susceptible) at time t is proportional to the density of the
infected (susceptible) population at time t, and we take ηI(ηS) to be the constants of
proportionality, respectively. Then at time t, the rate of tracing infected individuals is:
ηI
E (t) + I (t)
S0︸ ︷︷ ︸
probability of tracing an infected contact
· CT
︸ ︷︷ ︸
average number of infected contacts
traced per identified symptomatic case
·
(∫ Ti+Fi
Ts
µ (a) i (a, t) da
)
︸ ︷︷ ︸
rate of identifying symptomatic cases
(V.2)
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The rate of tracing susceptible individuals is:
ηS
S (t)
S0︸ ︷︷ ︸
probability of tracing
a susceptible contact
· CT
︸ ︷︷ ︸
average number of susceptible contacts
traced per identified symptomatic case
·
(∫ Ti+Fi
Ts
µ (a) i (a, t) da
)
︸ ︷︷ ︸
rate of identifying symptomatic cases
(V.3)
which are exactly the corresponding terms in (III.1) with the setting (V.1). Moreover,
the probability interpretations in (V.2) and (V.3) imply that for any time t, ηI and ηS
should satisfy:
ηI
E (t) + I (t)
S0
+ ηS
S (t)
S0
6 1 (V.4)
We denote the probability that a traced contact of an identified symptomatic individ-
ual is infected as η, a parameter that describes the tracing efficacy in finding infectives.
Hence ηI and ηS can be obtained when the value of η is given: ηI = η
S0
E(t)+I(t)
from (V.2),
and ηS 6 (1− η) S0S(t) by (V.3). Since S(t) is mostly unchanged for t in the initial phase of
the outbreak, for simplicity, we take S0
S(t)
≈ 1 and S0
E(t)+I(t)
≈ S0
E(0)+I(0)
for any time t. So ηI
and ηS are estimated by η and the initial conditions, i.e., ηI = η
S0
E(0)+I(0)
and ηS 6 1− η.
The value of η can be easily determined from evolving data during the initial phase of the
epidemic: it is simply the fraction of the traced contacts who turn out to be symptomatic
over all traced contacts.
In particular, when ηI = ηS = 1, then the probability of tracing an infected contact
at time t is η = E(t)+I(t)
S0
and that of tracing a susceptible contact at time t is S(t)
S0
. That
means the probability of tracing an infected (susceptible) contact at time t is exactly the
fraction of infected (susceptible) population at time t, which indicates that the tracing is
random and is not effective.
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V.2 Application I: Smallpox
V.2.1 Model for Mass Vaccination
Mass vaccination, usually conducted at a constant rate, is the strategy of vaccinating large
numbers of people. We assume that there is no residual immunity in the population,
and a post-event mass vaccination, together with a strategy of isolating symptomatic
individuals, start as soon as the first case is identified. We consider the fact that infected
people vaccinated in the first few days of exposure will not transmit smallpox to others
CDC (2004). And we denote Tv as the length of vaccine sensitive period for infectives,
that is, infectives receive vaccination with disease age less than Tv will not be infectious.
This assumption is not relevant in ring vaccination: infected contacts at any disease age
are removed due to vaccination and surveillance, hence Tv is a parameter that only used
in mass vaccination. Fig. V.2 shows the dynamic of the disease transmission with mass
vaccination.
S(t)
susceptible
Ev(t)
exposed
Eu(t)
exposed
I(t)
infectious
RI(t)
isolated due
to symptoms
R(t)
recovered
V (t)
successfully
vaccinated
Figure V.2: Ev(t) denotes the number of infectives in the vaccine sensitive stage, so they will
not transmit the disease to others if vaccinated. Eu(t) denotes the number of infectives in the
vaccine insensitive stage, who will be able to transmit the disease even after vaccination.
Based on the dynamics stated above, we have the corresponding disease age-structured
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model with mass vaccination as the only vaccination strategy that assists case isolation in
(V.5). The model is of a simpler form than (III.1), which can be analyzed by the method
in Webb et al (2010).
∂
∂t
i (a, t) +
∂
∂a
i (a, t) = −µ (a) i (a, t)− ν (a) i (a, t) , 0 6 a 6 Ti + Fi, t > 0
d
dt
S (t) = −
(∫ Ti+Fi
Ti
β (a) i (a, t) da
)
S (t)− ν0S (t) , t > 0
i (0, t) =
(∫ Ti+Fi
Ti
β (a) i (a, t) da
)
S (t) , t > 0
i (a, 0) = i0 (a) , 0 6 a 6 Ti + Fi, S (0) = S0
(V.5)
where ν (a) is the mass vaccination removal rate of infected individuals at disease age a,
ν0 is the mass vaccination rate, and the other notations have the same interpretations
as in the ring vaccination model. We can express different disease stages in Figure V.2
in terms of the infected population density function as: Ev (t) =
∫ Tv
0
i (a, t) da, Eu (t) =∫ Ti
Tv
i (a, t) da, and I (t) =
∫ Ti+Fi
Ti
i (a, t) da.
V.2.2 Model Parameters
Table 1 describes smallpox natural history and Table 2 shows parameter values/ranges
we choose for simulations. We pick the threshold values of Ti, Ts and Fi as recommended
in Eichner (2003) and CDC (2004). Fig. V.3a illustrates the transmission rate function
of disease age, the shape of the function suggested in studies Aldis and Roberts (2005),
Carrat et al (2008), Eichner (2003), CDC (2004), and Valle et al (2005), and we make
a theoretical estimation about the value of the transmission rate. We vary Rsym, the
percentage of symptomatic individuals removed per day, from 50% to 90%, which is an
estimation of an efficient removal process of smallpox due to its identifiable symptoms
after the prodrome.
24
We model a deliberate release of smallpox pathogen in a big city as large as New
York, which has a total population of 8× 106. All of the simulations start with an age
distribution of index cases as shown in Fig. V.3b, which corresponds to a scenario when
one or several public places encounter a series of smallpox virus releases.
Table 1. Smallpox durations of the progression stages.
Stage Duration Infectiousness References
Incubation period 7 ∼ 17 days Not infectious CDC (2004)
Initial symptoms(prodrome) 2 ∼ 4 days Sometimes infectious CDC (2004)
Early rash 4 days Most infectious CDC (2004)
Pustular rash and scabs 16 days Infectious CDC (2004)
Scabs resolved Not infectious CDC (2004)
TsTi Ti+Fi
0 10 20 30 40
0
5.´10-8
1.´10-7
1.5´10-7
2.´10-7
2.5´10-7
Age of infection a HdaysL
Tr
an
sm
iss
io
n
ra
te
Β
HaL
(a) Infection transmission rate function β (b) Initial disease-age distribution function i0
Figure V.3: Fig. V.3a is the infection age-dependent transmission rate function with respect
to age since infection. Ti, Ts, and Fi are introduced and estimated as in the context and Table
2. The grey area is the prodromal period with initial symptoms and early contagiousness. Fig.
V.3b is the initial disease distribution function i0.
V.2.3 Simulations of Different Vaccination Strategies: Mass Vaccination
versus Ring Vaccination
There are two ring vaccination scenarios in Fig. V.4: the green curves represent an effec-
tive ring vaccination strategy, and the blue curves represent an ineffective ring vaccination
strategy when ηI = ηS = 1. We observe pulses in the daily number of traced and vacci-
nated contacts in both of the two scenarios. These pulses are caused by the choice of the
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Tale 2. Baseline parameters and initial conditions.
Parameter description Parameter baseline value References
infectiousness threshold Ti = 12 days Eichner
(2003)
symptoms threshold Ts = 14 days CDC
(2004),
Eichner
(2003)
vaccine insensitiveness
threshold†
Tv = 3 days CDC
(2004)
length of infectious period Fi = 28 days CDC
(2004)
infection transmission rate
function
β (a) =

0 , 0 6 a < 12
2.5 · 10−8(a− 12)2e−0.5(a−12),
12 6 a 6 40
Fig. V.3a
removal of symptomatic
cases
Rsym > 50% per day Webb et al
(2010),
Meltzer
et al
(2001)
isolation rate of infectives µ (a) =
{
0.0, a 6 14
− ln (1.0−Rsym) , a > 14 Webb et al(2010)
mass vaccination removal
rate of infectives†
ν (a) =
{
ν0, 0 6 a 6 3
0, a > 3
CDC
(2004)
mass vaccination rate† 0 6 ν0 6 10000 Kaplan
et al
(2003)
average number of contacts
traced per identified case∗
0 < CT 6 100 Kaplan
et al
(2003)
probability for a traced
contact being infected∗
0 < η 6 1 Text
initial susceptible popula-
tion
S0 = 8× 106 Text
index cases distribution i0 ∈ L1+ [0, Ti + Fi] Fig. V.3b
∗parameters only used in ring vaccination.
†parameters only used in mass vaccination.
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Figure V.4: There are four different cases included in this figure. The green curves stand
for the case with effective ring vaccination when CT = 50, Rsym = 50%, and η = 0.1. The
blue curves represent the case with ineffective ring vaccination when CT = 50, Rsym = 50%,
and ηI = ηS = 1, so η =
I(t)+E(t)
S0
. The red curves are for the case with mass vaccination
when Rsym = 50% and the mass vaccination rate is 4000 individuals per day. The black curves
correspond to the case with an isolation removal rate of Rsym = 50% but no vaccination.
initial infection-age distribution function in Fig. V.3b. The majority of the index cases
are in an early disease age, and thus they will become infectious and symptomatic in the
same time period. As a consequence, symptomatic cases and generations of new cases
will appear as pulses; hence daily traced contacts will appear as pulses, since the tracing
rate depends on the isolation rate of symptomatic cases.
Fig. V.4 also gives comparison between ring and mass vaccination strategies from
different aspects: (1) the effective ring vaccination strategy prevents the most cases from
occurring and requires less personnel and less vaccine stockpiles; (2) the effective ring vac-
cination strategy does not require a large number of people to be traced everyday, and is
more efficient in controlling the outbreak compared to the mass vaccination (red curves),
which requires vaccination of a large number of people everyday; (3) the ineffective ring
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vaccination has similar results in controlling the outbreak as the mass vaccination (red
curves), even though it consumes less vaccine stockpiles in total; it requires extremely
heavy daily contact tracing load at times; (4) compared with the case of no vaccination
(black curves), mass vaccination and ineffective ring vaccination prevent hundreds of cases
from happening; (5) further simulations show that, for higherRsym values, non-vaccination
could control the spread of smallpox as well as mass vaccination and ineffective ring vac-
cination, while in contrast effective ring vaccination attains significant improvement in
reducing total number of cases.
We also take into consideration the fact that tracing, vaccinating, and surveilling a
contact in ring vaccination demands a different level of personnel effort than in mass
vaccination. So in Fig. V.5, we compare an effective ring vaccination of a highest daily
contact tracing rate of 4, 000 contacts per day, with a mass vaccination of a constant daily
vaccination rate of 12, 000 people per day. That is, we assume that tracing, vaccinating,
and surveilling a contact requires three times more effort than the comparable mass vac-
cination effort. As can be seen from the simulation, the effective ring vaccination prevents
more cases, and vaccinates less people than the mass vaccination, which would also help
reduce serious vaccination side effects.
V.2.4 Simulations of Ring Vaccination: Assessing Impacts of Parameters
In order to provide guidance to public health authorities for containment and surveillance
strategies, we vary the three variables, CT , η, and Rsym, to assess different levels of ring
vaccination by evaluating: (1) total number of infected cases, and (2) the percentage of
traced individuals.
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Figure V.5: The green curves stand for the case of an effective ring vaccination when CT = 50,
Rsym = 50%, and η = 0.1. The red curves are for the case of mass vaccination when Rsym = 50%
and the mass vaccination rate is 1, 2000 individuals per day.
total number of cases % of people traced
Figure V.6: The blue surface is the total number of cases as a function of daily removal
percentage of symptomatic cases 50% 6 Rsym 6 90%, and the probability that a traced contact
of an identified symptomatic individual is infected 0 < η 6 0.6. The number of contacts traced
per identified case is CT = 50. The green surface is the percentage of contact traced individuals
as a function of the same variables under the same settings.
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total number of cases % of people traced
Figure V.7: The blue surface is total number of infected cases as a function of daily removal
percentage of symptomatic cases 50% 6 Rsym 6 90%, and the average number of contacts
traced per identified case 10 6 CT 6 100. The probability for tracing an infected contact is
fixed as we take η = 0.1. The green surface is the percentage of contact traced population as a
function of the same variables under the same settings.
The simulation results in Fig. V.6 are intuitively reasonable: for fixed CT = 50, high
efficacies of both isolation and contact tracing will prevent more cases and save more
personnel engaged in tracing. Increasing η enables us to trace more infected contacts per
identified case, and it in turn saves personnel efforts. When the values of η and Rsym are
relatively small, increasing either one of them is efficient in both controlling the outbreak
and relieving the burden of tracing. If we are already able to maintain the isolation and
contact tracing at a relatively high level, increasing either of the two levels would require
more personnel to be involved, but just improve the results slightly.
We fix η = 0.1 in Fig. V.7, and notice that raising the value of CT does help reduce
the total number of cases, but it also boosts the demand for the number of health care
workers engaged in tracing, vaccinating, and surveilling. For fixed value of η, increasing
CT helps reduce infections in two ways: increasing the number of infected contacts traced
per identified case; and increasing the number of susceptible contacts quarantined which
30
total number of cases % of people traced
Figure V.8: The blue surface is attack ratio as a function of the probability that a traced
contact of an identified symptomatic individual is infected 0 < η 6 0.6, and the number of
contacts traced per identified case 10 6 CT 6 100. The daily removal percentage of symptomatic
cases is fixed as Rsym = 60%. The green surface is the percentage of contact traced population
as a function of the same variables under the same settings.
results in lower infection rates. Since large values of CT and Rsym require more public
health resources, it is left to the public health officials to determine appropriate levels of
contact tracing and isolation. In the case when an effective vaccination is absent, we do
not expect to quarantine a great amount of susceptibles, so the decision of increasing CT
should be carefully made.
In Fig. V.8, we assume that the removal percentage of symptomatic cases is fixed as
60%. CT and η represent different aspects of ring vaccination strategy, and this simulation
suggests how to deploy resources assigned in tracing and control the outbreak in a more
economical way. In contrast to Fig. V.7, when contact tracing is of higher efficacy in
finding infected contacts, increasing the average number of contacts provided by each
identified symptomatic case does not boost greatly the demand for personnel and vaccine
stockpiles. So under the assumption that the tracing efficiency η can be maintained while
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CT is increased, tracing more contacts per case will help prevent cases and will not result
in much more tracing work.
V.3 Application II: Influenzas: SARS
In this section, we apply our model to investigate contact tracing effectiveness in control
of modern influenzas and take the outbreak of SARS as an example. First, we use our
model to simulate the SARS outbreak in Taiwan, 2003 by real data. Then we modify the
length of presymptomatic period hypothetically in order to provide suggestions about the
efficacy of contact tracing under different circumstances. We apply our model to simulate
the SARS outbreak in Taiwan, 2003, concentrated in the Taipei-Keelung metropolitan
area (with a population of 6 million in 2003), because of the extensive available data and
the high efficiency of contact tracing in Taiwan.
V.3.1 Parameters
In Table 3, we list the parameters that are obtained from real data MMWR (2003) and
clinical studies of SARS. In MMWR (2003), we count the total number of traced close
contacts as 12, 394. Of those there are only 33 confirmed to be infected. In this way we
set η ≈ 33/12394 and CT ≈ 12394/300, where 300 is approximately the total number
of cases in Taipei-Keelung metropolitan area (which we refer to Taipei area for short in
the following context). The setting of the baseline values has three uncertain aspects: (1)
Ts − Ti determines the length of the incubation period: we set that to be 1.0 day in the
data fitting in subsection 6.2. (2) We make an assumption of the shape of transmission
rate function β based on laboratory diagnosis of SARS Carrat et al (2008), Peiris and
et al. (2003), Chan and et al. (2004), and determine its value by estimating the basic
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reproduction number of SARS in Taiwan as about 4.8 Hsieh et al (2004), Bauch et al
(2005). (3) We estimate the shape of the removal rate function of symptomatic individuals
µ by comparing it to studies Gumel et al (2004), Nishiura et al (2004), Carrat et al (2008).
We estimate the maximal value of µ in Fig. V.9b by fitting data of SARS in the Taipei
area.
Table 3. Baseline Parameters
Parameter description Baseline values References
infectiousness threshold Ti = 5.0 days Meltzer (2004), Hsu
and et al. (2003)
symptoms threshold Ts = 6.0 days Meltzer (2004), Hsu
and et al. (2003)
length of infectious period Fi = 21.0 days Meltzer (2004), Hsu
and et al. (2003)
isolation rate of infectives Fig. V.9b Gumel et al (2004),
Nishiura et al (2004)
infection transmission rate function Fig. V.9a Hsieh et al (2004),
Bauch et al (2005),
Carrat et al (2008),
Peiris and et al. (2003),
Chan and et al. (2004)
average number of contacts traced
per identified case
CT ≈ 12394/300 MMWR (2003)
probability for a traced contact be-
ing infected
η ≈ 33/12394 MMWR (2003)
initial susceptible population S0 = 6× 106 Text
index cases distribution Fig. V.9c Hsieh et al (2004),
MMWR (2003)
V.3.2 Data Fitting
Our simulation results are shown in Fig. V.10. Compared to simply using isolation of
symptomatic cases, enforced contact tracing can help prevent 40 individuals from being
infected. That means contact tracing and quarantine of more than 12, 000 people in the
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(a) Infection transmission rate
function β
(b) Removal rate function µ (c) Initial disease age distribu-
tion i0
Figure V.9: The β, µ, and i0 functions we use to fit the SARS data in Taiwan, 2003.
Taipei area enabled public health officials to discover 33 infected cases, and thus about 7
cases were avoided.
Figure V.10: The blue dots are the real data from the SARS outbreak in Taipei-Keelung
metropolitan area, 2003. The green curves represent our simulation to fit the real data with
parameters in Table 3. The red curves stand for the assumption that there is only isolation of
symptomatic cases but no contact tracing implemented.
V.3.3 Alternative Fitting Parameters
In Fig. V.11, we modify two of the uncertain parameters mentioned before, the length of
presymptomatic period Ts − Ti and the removal rate of symptomatic infectives (which is
the highest value of the removal rate function µ), and fit the data from Taiwan SARS.
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Figure V.11: The blue curve stands for pairs
of parameters, incubation period length Ts−Ti
and maximum removal rate of symptomatic
infectives, that can be applied in our model in
order to fit the outbreak data of SARS, Taipei
area. The red dot is the pair of parameter we
used in the data fitting Fig. V.10. Further
simulation indicates that the number of cases
that are avoided by contact tracing remains
the same no matter which pair of the param-
eters we take.
As can be inferred from Fig. V.11, longer incubation period requires higher efficiency of
symptomatic case isolation in order to maintain the total number of cases at the same
level. As a consequent result, we observe that the number of cases that are avoided by
contact tracing under all pairs of parameters in Fig. V.11 is as much as 40. Which means,
we can assess the effectiveness of contact tracing in SARS, Taiwan without an accurate
estimation of the incubation period since different assumptions lead to similar results.
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CHAPTER VI
DISCUSSIONS AND FUTURE WORK
We have introduced a general epidemic model that takes age since infection into con-
sideration, to model interventions such as contact tracing, quarantine, and vaccination.
Our model is applicable to different control strategies that can be formulated consistent
with the hypotheses (A.1) − (A.3). The global existence, uniqueness, and asymptotic
behaviour of solutions are proved in the appendix. The theoretical results in Section 3
are true for non-linear age-dependent models with aging and birth functions satisfying
(H.1) and (H.2), where (H.2) applies to different conditions than that in Webb (1985).
Compared to previous models with infection age as a continuous variable, we are able
to incorporate some important aspects of the spread and control of an epidemic disease
in the model, together with practical interpretations of the corresponding parameters.
For example, (i) by considering the simplified fact that the tracing rate varies according
to case identification rate, we will be able to understand one of the reasons for small
fluctuations that usually appear in daily cases in many of the real data; (ii) decrease of
susceptible population due to public health interventions is not negligible when the inter-
ventions successfully protect a considerable amount of people from infection.
In application I, we use our model to assess public health guidelines in the event of
a smallpox bioterrorist attack in a large urban center. Our simulation falls into the sce-
nario that releases of the virus take place in the community with people being unaware of
them. But we can easily modify the initial conditions to simulate other initial scenarios,
such as when index cases are introduced into the community by a smallpox release in
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another area, while the government and the public are getting prepared and in a watchful
state. Our simulation results point out that with a limited amount of vaccine stockpiles
and healthcare workers, ring vaccination is more efficient in preventing the disease from
spreading than mass vaccination. With the initial condition in Fig. V.3b, there are not
many people in the vaccination queue at the beginning of the outbreak. In this case,
ring vaccination allows the early vaccine distribution for selected groups to enhance the
response readiness CDC (2003), and hence allows more efficient utilization of vaccination
capacity.
We also investigate the ring vaccination effectiveness by varying the three key param-
eters: isolation rate, contacts traced per case, and contact tracing efficiency in finding
infectives. Fig. V.6 and Fig. V.7 also confirm the conclusion in Day et al (2006): trac-
ing and quarantine help avert more cases when the isolation of symptomatic cases is
ineffective. Additionally, we show that in the case of smallpox, the effectiveness of ring
vaccination in reducing infections increases at an accelerating rate as the effectiveness of
isolation diminishes1 when the ring vaccination efficacy is of a normal level, but it in-
creases at an almost constant lower rate when the ring vaccination efficacy is of a higher
level.
Our model is able to provide guidance to public health decisions to adjust current
contact tracing strategies either before or during an outbreak with updated data. All
the parameters in our model have good epidemiological interpretations and are easy to
estimate with data from historical epidemic outbreaks. Unlike many other studies, we
take into consideration susceptible population variation due to quarantine and vaccina-
1Quote from Day et al (2006)
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tion, which usually leads to community herd immunity. So when vaccines are available,
our model can be applied to provide guidelines for vaccination strategies to create herd
immunity2.
In application II, we show that our simulation of SARS in Taiwan fits well with the
observed data, and we are able to answer the question about how many cases are avoided
by implementing contact tracing and quarantine in the control of the outbreak. With
more precise data about each identified case, we would be able to estimate the case isola-
tion rate accurately, and our model would enable us to determine the length of incubation
period by data fitting. Therefore, our model would also be helpful in estimating important
parameters and predicting transmission dynamics with evolving data during an outbreak.
A great difference between the two applications we present in the paper is, contact tracing
applied to control SARS in Taiwan, 2003 is not as effective as ring vaccination strategy in
eradicating smallpox. The theoretical reason is that we have different settings of contact
tracing parameters CT , ηI , and ηS in the two applications. In reality, our settings are
quite reasonable due to facts such as the severity of symptoms, availability of vaccines
(since vaccination is an important way to create herd immunity), and readiness of the
public health officials with the preparedness and containment plans.
Our simulations can guide public health officials in adjusting levels of different strate-
gies to control the outbreak and deploy resources efficiently. With theoretical sugges-
tions, realistic adjustments about how to deploy limited resources (such as vaccine stock-
piles, healthcare workers, surveillance stations, etc.) to meet the theoretical levels would
strongly depend on the decisions of public health authorities. Furthermore, with cost-
2A historical example is the ”ring” vaccination strategy used to eliminate smallpox
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effectiveness data, we can apply optimal control methods to quantitatively determine the
best control strategies.
Furthermore, the age-structured model possesses great potential in modeling the vac-
cination strategy of HIV (although the HIV vaccine does not exist so far, several en-
couraging studies such as Hansen and et al. (2013) suggest that there is a significant
hope in the future). The HIV infection has an extremely long asymptomatic period and
many HIV-positive people are unaware of their infection with the virus. Thus, an active
infected individual would spread the disease without even being aware of the infection,
which makes the control and detection of HIV very difficult. Even though we might have
an HIV vaccine available in the future, with possible serious side-effects, it might be too
limited and costly to be available to everyone at the beginning. So the deployment of a
limited amount of vaccine will be a serious issue. Then, because of the prolonged asymp-
tomatic stage of HIV infection, the effects of certain intervention strategies would depend
even more on the age of infection. Our model will be an advantageous starting point for
such investigation.
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CHAPTER VII
PROOFS OF THE THEORETICAL RESULTS
VII.1 Theorem III.4.1
Theorem III.4.1 can be proved by the following three propositions:
Proposition VII.1.1. Let (H.1), (H.2) hold, let T > 0, let φ ∈ L1, and let l ∈ CT . If l
is a solution of the integral equation:
l (t) (a) =
(F (l)) (t− a) +
∫ t
t−aG (l (s)) (s+ a− t) ds, 0 < a < t
φ (a− t) + ∫ t
0
G (l (s)) (s+ a− t) ds, t ≤ a ≤ M
(VII.1)
on [0, T ], then l is a solution of (III.4) on [0, T ].
Proof. The proof is similar to that of Proposition 2.1 in Webb (1985), except that we
can use the uniform continuity of the function t 7→ (F (l)) (t) from [0, T ] to R for l ∈ CT
instead in this proof.
Proposition VII.1.2. Let (H.1), (H.2) hold and let r > 0. There exists T > 0 such that
if φ ∈ L1 and ‖φ‖L1 ≤ r, then there is a unique function l ∈ CT such that l is a solution
of (VII.1) on [0, T ].
Proof. We will prove it by contraction mapping theorem. We fix r > ‖φ‖L1 > 0 and
choose T > 0 such that
T ·
c1 (2r) + c2 (2r, T ) + sup0≤t≤T |(F (0)) (t)|+ ‖G (0)‖L1
2r
 ≤ 1
2
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Then define S as a closed subset of CT :
S :=
{
l ∈ CT : l (0) = φ, ‖l‖CT ≤ 2r
}
We define a mapping K on S as following and prove that K is a strict contraction from
S into S.
(K (l)) (t) (a) =
(F (l)) (t− a) +
∫ t
t−aG (l (s)) (s+ a− t) ds, a.e. a ∈ (0, t)
φ (a− t) + ∫ t
0
G (l (s)) (s+ a− t) ds, a.e. a ∈ [t,M]
we need to verify that the following conditions hold:
(i) Let l ∈ S, t ∈ [0, T ], then ‖(K (l)) (t)‖L1 6 2r.
(ii) Let l ∈ S and let 0 ≤ t < tˆ ≤ T , then ∥∥(K (l)) (t)− (K (l)) (tˆ)∥∥
L1
→ 0 as ∣∣tˆ− t∣∣→
0.
(iii) Let l1, l2 ∈ S, then ‖K (l1)−K (l2)‖CT ≤ 12‖l1 − l2‖CT .
For (i), we will only consider the case when 0 ≤ t ≤ min{M, T}. (Otherwise, we have
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t > M > a, then we just need to consider the expression of (K (l)) (t) (a) for a ∈ (0, t).)
‖(K (l)) (t)‖L1 =
∫ M
0
|(K (l)) (t) (a)| da
6
∫ t
0
∣∣∣∣(F (l)) (t− a) + ∫ t
t−a
G (l (s)) (s+ a− t) ds
∣∣∣∣ da
+
∫ M
t
∣∣∣∣φ (a− t) + ∫ t
0
G (l (s)) (s+ a− t) ds
∣∣∣∣ da
6
∫ t
0
|(F (l)) (s)| ds+
∫ M−t
0
|φ (s)| ds+
∫ t
0
∫ M
t−s
|G (l (s)) (s+ a− t)| dads
6
∫ t
0
|(F (l)) (s)− (F (0)) (s)| ds+
∫ t
0
|(F (0)) (s)| ds+
∫ M
0
|φ (s)| ds
+
∫ t
0
‖G (l (s))−G (0)‖L1ds+
∫ t
0
‖G (0)‖L1ds
6c2 (2r, t)
∫ t
0
sup
06τ6s
‖l (τ)‖L1ds+ t · sup
06s6t
|(F (0)) (s)|+ ‖φ‖L1
+ c1 (2r)
∫ t
0
‖l (s)‖L1ds+ t · ‖G (0)‖L1
≤2rT
c1 (2r) + c2 (2r, T ) + sup0≤t≤T |(F (0)) (t)|+ ‖G (0)‖L1
2r
+ r ≤ 2r
For (ii), we can just follow the same estimation in the proof of Proposition 2.2 in Webb
(1985), except that we need to use the uniform continuity of the function t 7→ (F (l)) (t)
from [0, T ] to R for l ∈ CT . (i) and (ii) imply that K maps S into S, (iii) shows that K
is a contraction.
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To prove (iii), given any l1, l2 ∈ S, we consider 0 ≤ t ≤ min{M, T}. Similarly we have:
∫ M
0
|(K (l1)) (t) (a)− (K (l2)) (t) (a)| da
≤
∫ t
0
|(F (l1)) (s)− (F (l2)) (s)| ds+
∫ t
0
‖G (l1 (s))−G (l2 (s))‖L1ds
≤
∫ t
0
c2 (2r, s) sup
06τ6s
‖l1 (τ)− l2 (τ)‖L1ds+ c1 (2r)
∫ t
0
‖l1 (s)− l2 (s)‖L1ds
≤T · [c1 (2r) + c2 (2r, T )] ‖l1 − l2‖CT ≤
1
2
‖l1 − l2‖CT
Proposition VII.1.3. Let (H.1), (H.2) hold, let φ, φˆ ∈ L1, let T > 0, and let l, lˆ ∈ CT
such that l, lˆ is the solution of (III.4) on [0, T ] for φ, φˆ, respectively. Let r > 0 such that
‖l‖CT ,
∥∥∥lˆ∥∥∥
CT
≤ r. Then for 0 ≤ t ≤ T ,
∥∥∥l (t)− lˆ (t)∥∥∥
L1
6 e[c1(r)+c2(r,T )]t
∥∥∥φ− φˆ∥∥∥
L1
Hence we have the uniqueness of the local solution of (III.4).
Proof. For each t ∈ [0, T ] we define two continuous functions:
(1) V (t) :=
∥∥∥l (t)− lˆ (t)∥∥∥
L1
=
∫ M−t
−t
∣∣∣l (t) (t+ c)− lˆ (t) (t+ c)∣∣∣ dc
(2) W (t) := sup
06s6t
∥∥∥l (s)− lˆ (s)∥∥∥
L1
= sup
06s6t
V (s)
Next, we estimate lim sup
h→0+
h−1 [W (t+ h)−W (t)] for each fixed t ∈ [0, T ] separately under
the following two situations:
(i) V (t) < W (t) (as shown in Fig. VII.1), i.e., ∃t0 < t such that W (t) = V (t0) > V (t).
Since the mapping s 7→ V (s) is continuous, we can choose sufficiently small h > 0
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such that V (t+ δ) 6 V (t0) for 0 6 δ 6 h, hence W (t+ δ) = W (t) for 0 6 δ 6 h.
Then lim sup
h→0+
h−1 [W (t+ h)−W (t)] = 0.
Figure VII.1
(ii) V (t) = W (t), i.e., the function V attains the supremum value in [0, t] at t. Then
we have
h−1 [W (t+ h)−W (t)] = h−1
[
sup
06s6t+h
V (s)− V (t)
]
=h−1
[
max
{
V (t) , sup
t≤s≤t+h
V (s)
}
− V (t)
]
≤ h−1
∣∣∣∣ sup
t≤s≤t+h
V (s)− V (t)
∣∣∣∣
≤h−1 sup
t6s6t+h
|V (s)− V (t)| = sup
06h06h
h0
h
h−10 |V (t+ h0)− V (t)|
6 sup
06h06h
h−10 |V (t+ h0)− V (t)|
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For each h0 ∈ [0, h], we estimate
h−10 [V (t+ h0)− V (t)]
=h−10
∫ −t
−t−h0
∣∣∣l (t+ h0) (t+ h0 + c)− lˆ (t+ h0) (t+ h0 + c)∣∣∣ dc
+ h−10
∫ M−t−h0
−t
∣∣∣l (t+ h0) (t+ h0 + c)− lˆ (t+ h0) (t+ h0 + c)∣∣∣ dc
− h−10
∫ M−t
−t
∣∣∣l (t) (t+ c)− lˆ (t) (t+ c)∣∣∣ dc
6h−10
∫ h0
0
|l (t+ h0) (a)− (F (l)) (t)| da
+ h−10
∫ h0
0
∣∣∣(F (l)) (t)− (F (lˆ)) (t)∣∣∣ da
+ h−10
∫ h0
0
∣∣∣(F (lˆ)) (t)− lˆ (t+ h0) (a)∣∣∣ da
+
∫ M
0
∣∣h−10 [l (t+ h0) (a+ h0)− l (t) (a)]−G (l (t)) (a)∣∣ da
+
∫ M
0
∣∣∣G (l (t)) (a)−G(lˆ (t)) (a)∣∣∣ da
+
∫ M
0
∣∣∣h−10 [lˆ (t+ h0) (a+ h0)− lˆ (t) (a)]−G(lˆ (t)) (a)∣∣∣ da
So for both of the above situations, notice that both l and lˆ are solutions of problem
(III.4), we can estimate as the following:
lim sup
h→0+
h−1 [W (t+ h)−W (t)] 6 lim sup
h→0+
sup
06h06h
h−10 |V (t+ h0)− V (t)|
6
∣∣∣(F (l)) (t)− (F (lˆ)) (t)∣∣∣+ ∥∥∥G (l (t))−G(lˆ (t))∥∥∥
L1
6c2 (r, t) sup
06s6t
∥∥∥l (s)− lˆ (s)∥∥∥
L1
+ c1 (r)
∥∥∥l (t)− lˆ (t)∥∥∥
L1
6 [c1 (r) + c2 (r, T )]W (t)
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So we have W (t) 6 e[c1(r)+c2(r,T )]tW (0) (Lakshmikantham and Leela (1969), Theorem
1.4.1). Hence,
V (t) 6 W (t) 6 e[c1(r)+c2(r,T )]tW (0) = e[c1(r)+c2(r,T )]t
∥∥∥φ− φˆ∥∥∥
L1
That is, ∥∥∥l (t)− lˆ (t)∥∥∥
L1
6 e[c1(r)+c2(r,T )]t
∥∥∥φ− φˆ∥∥∥
L1
VII.2 Theorem III.4.3 and Theorem III.4.4
Proof of Theorem III.4.3 and Theorem III.4.4. The proof of Theorem III.4.3 and Theo-
rem III.4.4 are similar to that of the corresponding theorems in Sections 2.3−2.4 in Webb
(1985). We only need to switch the statement of Proposition 2.4 in Webb (1985) to the
following Proposition VII.2.1.
Proposition VII.2.1. Let (H.1), (H.2) hold, let φ ∈ L1, let T > 0, and let l ∈ CT such
that l is a solution of (VII.1) on [0, T ]. Let Tˆ > 0 and let lˆ ∈ CT+T such that lˆ (t) = l (t)
for t ∈ [0, T ], and for t ∈
(
T, T + Tˆ
]
, lˆ satisfies the following integral equation:
lˆ (t) (a) =

(
F
(
lˆ
))
(t− a) + ∫ t
t−aG
(
lˆ (s)
)
(s+ a− t) ds, 0 < a < t− T
l (T ) (a− t+ T ) + ∫ t
T
G
(
lˆ (s)
)
(s+ a− t) ds, t− T 6 a 6 M
Then lˆ is a solution of (VII.1) on
[
0, T + Tˆ
]
.
Proof. First of all, we notice that if (H.2) holds, then (F (l)) (t) =
(
F
(
lˆ
))
(t) for t ∈
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[0, T ]. Because for any t ∈ [0, T ], by (H.2), ∃C > 0 such that
∣∣∣(F (l)) (t)− (F (lˆ)) (t)∣∣∣ 6 C sup
06s6t
∥∥∥l (s)− lˆ (s)∥∥∥
L1
= 0
Then it is easy to verify that lˆ is a solution to (VII.1) for t ∈ [0, T ]. Next, we verify that
lˆ is a solution to (VII.1) for t ∈
(
T, T + Tˆ
]
.
For t− T 6 a 6 M:
1. If a > t,
lˆ (t) (a) = l (T ) (a− t+ T ) +
∫ t
T
G
(
lˆ (s)
)
(s+ a− t) ds
= (F (l)) (t− a) +
∫ T
t−a
G (l (s)) (s+ a− t) ds+
∫ t
T
G
(
lˆ (s)
)
(s+ a− t) ds
=
(
F
(
lˆ
))
(t− a) +
∫ t
t−a
G
(
lˆ (s)
)
(s+ a− t) ds
2. If a < t,
lˆ (t) (a) = l (T ) (a− t+ T ) +
∫ t
T
G
(
lˆ (s)
)
(s+ a− t) ds
= φ (a− t) +
∫ T
0
G (l (s)) (s+ a− t) ds+
∫ t
T
G
(
lˆ (s)
)
(s+ a− t) ds
= φ (a− t) +
∫ t
0
G
(
lˆ (s)
)
(s+ a− t) ds
For 0 6 a 6 t− T , the verification is straightforward.
VII.3 Theorem IV.1.1
Proof of Theorem IV.1.1. By Theorem III.4.3 and Theorem III.4.4, We only need to show
that the aging function G in (P.1) and the birth function F in (P.2) satisfy the hypotheses
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(H.1) − (H.5). (H.3) and (H.4) are obvious from (P.1) and (P.2), we will justify (H.1)
and (H.2) as follows. First denote µ¯ := ‖µ‖L∞ . Let r > 0, for any φ1, φ2 ∈ L1 such that
‖φ1‖L1 , ‖φ2‖L1 ≤ r, we have
‖G (φ1)−G (φ2)‖L1
6
∫ M
0
µ (a) |φ1 (a)− φ2 (a)| da+ T (φ1)
∫ M
0
|φ1 (a)− φ2 (a)| da
+ |T (φ1)− T (φ2)|
∫ M
0
|φ2 (a)| da
6 (µ¯+ 2r‖T ‖∞) ‖φ1 − φ2‖L1
so we have (H.1). In order to prove (H.2), first we notice that t 7→ (F (φ)) (t) is continuous
in [0,∞) for any φ ∈ CT . So F : CT → C ([0, T ] ;R).
Next, for any φ1, φ2 ∈ CT such that ‖φ1‖CT , ‖φ2‖CT ≤ r, we have ∀t ∈ [0, T ],
|(F (φ1)) (t)− (F (φ2)) (t)|
≤S0 |B (φ1 (t))− B (φ2 (t))| e−
∫ t
0 B(φ1(s))+Q(φ1(s))ds
+ S0B (φ2 (t))
∣∣∣e− ∫ t0 B(φ1(s))+Q(φ1(s))ds − e− ∫ t0 B(φ2(s))+Q(φ2(s))ds∣∣∣
= : I1 + I2
Obviously, I1 ≤ S0|B|‖φ1 (t)− φ2 (t)‖L1ert(|Q|+|B|).
In order to consider I2, notice that
∣∣eX − eY ∣∣ ≤ eM |X − Y | for |X|, |Y | ≤ M. Then we
have
I2 6 S0|B|rert(|Q|+|B|)
∫ t
0
|B (φ1 (s)) +Q (φ1 (s))− B (φ2 (s))−Q (φ2 (s))| ds
≤S0|B|rert(|Q|+|B|) (|B|+ |Q|)
∫ t
0
‖φ1 (s)− φ2 (s)‖L1ds
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Hence,
|(F (φ1)) (t)− (F (φ2)) (t)|
≤S0 |B| ert(|Q|+|B|) [1 + rt (|B|+ |Q|)] sup
06s6t
‖φ1 (s)− φ2 (s)‖L1
Now we let l ∈ C ([0, Tφ) ;L1+) be the positive solution of (III.4), then for any t ∈ [0, Tφ),
(H.5) is easy to verify:
(F (l)) (t) +
∫ M
0
G (l (t)) (a) da 6 S0 |B|
∫ M
0
l (t) (a) da
So by Theorem III.4.4, there is a positive global solution of (III.4).
VII.4 Proposition IV.2.1
Proof of Proposition IV.2.1. Proof of the existence of the global positive solution is based
on the following four lemmas. An easy computation can be done to testify that a solution
of (IV.1) is also a solution in the sense of (III.4) with aging function P and birth function
H.
Lemma VII.4.1. Let the assumptions in Proposition IV.2.1 hold, and let r > 0. There
exists T > 0 such that if ‖φ‖L1 6 r, then there is a unique function u ∈ CT,+ such that u
is a solution of (IV.1) on [0, T ].
Proof. We can choose a sufficiently small T > 0 and define
S :=
{
u ∈ CT,+ : u (t) = φ, ‖u‖CT 6 2r
}
An argument which is similar to that of Proposition VII.1.2 can be used to show that a
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mapping defined by (IV.1) from S into S is a strict contraction. Thus, the unique fixed
point is a positive solution of (IV.1) in CT,+.
Lemma VII.4.2. Let the assumptions in Proposition IV.2.1 hold, let T > 0, and let
u ∈ CT,+ such that u is a solution of (IV.1) on [0, T ]. Let Tˆ > 0 and let uˆ ∈ CT+Tˆ ,+ such
that uˆ (t) = u (t) for t ∈ [0, T ], and for t ∈
(
T, T + Tˆ
]
, uˆ satisfies the integral equation:
uˆ(t)(a) =
(H (uˆ))(t− a) e
− ∫ a0 µ(b)db, 0 < a < t− T
u (T )(a− t+ T ) e−
∫ a
a−t+T µ(b)db, t− T ≤ a ≤ M
where H is as stated in Proposition IV.2.1. Then uˆ is a solution of (IV.1) on
[
0, T + Tˆ
]
.
Proof. The proof is similar to that of Proposition VII.2.1.
Lemma VII.4.3. Let the assumptions in Proposition IV.2.1 hold, let φ ∈ L1+, and let u
be the solution of (IV.1) on its maximal interval of existence [0, Tφ). If Tφ < ∞, then
lim sup
t→Tφ−
‖u (t)‖L1 =∞.
Proof. The proof is similar to that of Theorem 2.3 in Webb (1985).
Lemma VII.4.4. Let the assumptions in Proposition IV.2.1 hold, let φ ∈ L1+, and let
u be the positive solution of (IV.1) on its maximal interval of existence [0, Tφ). Then
∃ω ∈ R, and for t ∈ [0, Tφ), ‖u (t)‖L1 6 ‖φ‖L1eωt. So Tφ = ∞, there is a global positive
solution of (IV.1).
Proof. For t ∈ [0, Tφ), we estimate as follows (here we assume t 6 M, then t > M leads
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to a simpler case):
‖u (t)‖L1 =
∫ M
0
u (t)(a) da 6
∫ t
0
(H (u)) (t− a) da+
∫ M
t
φ (a− t) da
6
∫ t
0
S0 |B| ‖u (t− a)‖L1da+
∫ M
t
φ (a− t) da
6S0 |B|
∫ t
0
‖u (s)‖L1ds+
∫ M−t
0
φ (s) ds
6S0 |B|
∫ t
0
‖u (s)‖L1ds+ ‖φ‖L1
Then by Gronwall’s Inequality, we have ‖u (t)‖L1 6 ‖φ‖L1eS0|B|t. Then by Lemma VII.4.3,
Tφ =∞, hence there is a positive global solution to (IV.1).
VII.5 Theorem IV.3.1
Proof of Theorem IV.3.1. Let T > 0, we assume that u ∈ C ([0, T ] ;L1+) satisfies (IV.1)
for t ∈ [0, T ], then u satisfies the following conditions:
lim
h→0+
∫ M
0
∣∣h−1 [u (t+ h) (a+ h)− u (t) (a)] + µ (a)u (t) (a)∣∣ da = 0
lim
h→0+
h−1
∫ h
0
|u (t+ h) (a)− (H (u)) (t)| da = 0
u (0) = φ
(VII.2)
We will show that l ∈ C ([0, T ] ;L1+) as obtained from (IV.2), satisfies (III.4) with the
aging function G in (P.1) and the birth function F in (P.2). For the first condition in
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(III.4), we have the following estimation:
h−1 [l (t+ h) (a+ h)− l (t) (a)] + µ (a) l (t) (a) + T (l (t)) l (t) (a)
=
h−1 [u (t+ h) (a+ h)− u (t) (a)] + µ (a)u (t) (a)
1 +
∫ t+h
0
T (u (s)) ds
+
[
µ (a)u (t) (a)
1 +
∫ t
0
T (u (s)) ds −
µ (a)u (t) (a)
1 +
∫ t+h
0
T (u (s)) ds
]
+h−1
[
u (t) (a)
1 +
∫ t+h
0
T (u (s)) ds
− u (t) (a)
1 +
∫ t
0
T (u (s)) ds
]
+
T (u (t))u (t) (a)(
1 +
∫ t
0
T (u (s)) ds
)2
:=I1 + I2 + I3
By (VII.2), I1 → 0 as h → 0. I2 → 0 as h → 0 because of the absolute continuity of
Lebesgue integral. If we compute the derivative of function f (t) := 1
1+
∫ t
0 T (u(s))ds
, we get
I3 → 0 as h → 0. Hence the first limit in the solution definition (III.4) is satisfied. For
the second condition in (III.4), we have
∫ h
0
|l (t+ h) (a)− (F (l)) (t)|da
=
∫ h
0
∣∣∣l (t+ h) (a)− S0B (l (t)) e− ∫ t0 B(l(s))+Q(l(s))ds∣∣∣ da
=
∫ h
0
∣∣∣∣∣u (t+ h) (a)− (H (u)) (t)1 + ∫ t
0
T (u (s)) ds
∣∣∣∣∣da→ 0, (h→ 0+)
The third condition in (III.4) is straightforward. Then by Proposition IV.2.1, we can find
a u ∈ C ([0,∞) ;L1+) that satisfies (IV.1). Then a positive global solution to problem
(III.4) can be obtained by (IV.2), which is exactly the unique positive global solution to
(III.4).
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VII.6 Theorem IV.4.1
Proof of Theorem IV.4.1. Let u ∈ C ([0,∞) ;L1+) be the solution to (IV.1), and let i ∈
C
(
[0,∞) ;L1+
)
as defined in (IV.2), which is a solution to problem (III.1) in the sense
of (III.4). For convenience in this proof, we use the notation i (a, t) := i (t)(a) and
u (a, t) := u (t)(a), for a ∈ [0,M] , t ∈ [0,∞). Firstly, by (III.1) we have
S (t) = S0e
− ∫ t0 B(i(·,s))+Q(i(·,s))ds
which is a positive non-increasing continuous function of t ∈ [0,∞). So lim
t→∞
S (t) exists,
and we denote it as lim
t→∞
S (t) = S∞ > 0. Next we estimate the following:
∫ ∞
0
B (i (·, t)) +Q (i (·, t)) dt 6
∫ ∞
0
(|B|+ |Q|) ‖i (·, t)‖L1dt
= (|B|+ |Q|)
∫ ∞
0
∫ M
0
u (a, t)
1 +
∫ t
0
T (u (·, s)) dsdadt
= (|B|+ |Q|)
∫ M
0
∫ a
0
φ (a− t) e−
∫ a
a−t µ(b)db
1 +
∫ t
0
T (u (·, s)) dsdtda
+ (|B|+ |Q|)
∫ M
0
∫ ∞
a
u (0, t− a) e−
∫ a
0 µ(b)db
1 +
∫ t
0
T (u (·, s)) ds dtda
:= (|B|+ |Q|) (I1 + I2)
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Estimate I1 and I2 separately:
I1 6
∫ M
0
∫ a
0
φ (a− t) e−
∫ a
a−t µ(b)dbdtda =
∫ M
0
∫ a
0
φ (s) e−
∫ a
s µ(b)dbdsda
=
∫ a0
0
∫ a
0
φ (s) e−
∫ a
s µ(b)dbdsda+
∫ M
a0
∫ a
0
φ (s) e−
∫ a
s µ(b)dbdsda
6
∫ a0
0
∫ a
0
φ (s) dsda+
∫ M
a0
∫ a
0
φ (s) e−µ0(a−s)dsda
6a0‖φ‖L1 +
∫ M
0
∫ a
0
φ (s) e−µ0(a−s)dsda
=a0‖φ‖L1 +
∫ M
0
∫ M
s
φ (s) e−µ0(a−s)dads
=a0‖φ‖L1 +
∫ M
0
∫ M−s
0
φ (s) e−µ0τdτds
6a0‖φ‖L1 +
∫ M
0
∫ M
0
φ (s) e−µ0τdτds
=a0‖φ‖L1 +
(∫ M
0
e−µ0τdτ
)
‖φ‖L1 <∞
I2 =
∫ M
0
∫ ∞
a
u (0, t− a) e−
∫ a
0 µ(b)db
1 +
∫ t
0
T (u (·, s)) ds dtda
6
∫ M
0
∫ ∞
0
u (0, τ) e−
∫ a
0 µ(b)db
1 +
∫ a+τ
0
T (u (·, s)) dsdτda
6
∫ M
0
∫ ∞
0
u (0, τ) e−
∫ a
0 µ(b)db
1 +
∫ τ
0
T (u (·, s)) dsdτda
=
(∫ ∞
0
i (0, τ) dτ
)(∫ M
0
e−
∫ a
0 µ(b)dbda
)
6
(∫ ∞
0
i (0, τ) dτ
)(
a0 +
∫ M
a0
e−aµ0da
)
With the assumption on function µ, we can find constants C1, C2 > 0 such that:
∫ ∞
0
B (i (·, t)) +Q (i (·, t)) dt 6 C1 + C2
∫ ∞
0
i (0, t) dt
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Since i is obtained from (IV.2), we have:
i (0, t) =
u (0, t)
1 +
∫ t
0
T (u (·, s)) ds = S (t)B (i (·, t))
Then by the differential equation of S(t) in (III.1), we have:
i (0, t) = −dS (t)
dt
−Q (i (·, t))S (t) 6 −dS (t)
dt
Integrate on both sides with respect to t of the above inequality,
∫ ∞
0
i (0, t) dt 6 S0 − S∞ <∞
Hence one of the conclusion is proved:
lim
t→∞
S (t) = S0e
− ∫∞0 B(i(·,s))+Q(i(·,s))ds > S0e−C1−C2 ∫∞0 i(0,t)dt > 0
Moreover, it can be derived from the differential equation system (III.1) that:
S (t) + I (t) +
∫ t
0
Q (i (·, s)) I (s) ds+
∫ t
0
T (i (·, s)) I (s) ds+
∫ t
0
i (M, s) ds
+
∫ t
0
∫ M
0
µ (a) i (a, s) dads = S0 + I (0)
(VII.3)
where the four integrals in (VII.3) are non-decreasing with respect to the variable t
and have S0 + I (0) as an upper bound. So the four integrals all have finite limit as
t→∞. Then the fact that lim
t→∞
S (t) exists implies that lim
t→∞
I (t) exists. We can estimate∫∞
0
I (t) dt =
∫∞
0
‖i (t)‖L1dt similarly as we did in the beginning of this proof and get∫∞
0
I (t) dt <∞, which implies the conclusion lim
t→∞
I (t) = 0.
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